Clinical Trial Update: Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated Rebif (interferon beta-1a) delivered via the RebiSmart device for effectiveness in Clinically Isolated Syndrome and Relapsing Multiple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Relapsing Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2018-03-30